Navigation Links
Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Date:5/6/2010

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at two investor conferences in the coming week.  David Loury PhD, Chief Scientific Officer, will be presenting at the MDB Bright Lights Conference in San Francisco, CA at the Palace Hotel on Tuesday, May 11 at 4:00 P.M. PDT.  Joseph Buggy PhD, Vice President of Research, will be presenting at the Bank of America Merrill Lynch Healthcare Conference in New York, NY at the Grand Hyatt on Wednesday, May 12 at 4:20 P.M. EDT/1:20 P.M. PDT.

There will be a live webcast of the Bank of America Merrill Lynch conference presentation, which will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our mission and goal are worth repeating: to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
2. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
3. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
4. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
5. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
6. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
7. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
8. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... DHABI , Saudi Arabia , January 22, 2017 /PRNewswire/ ... the US and UAE ... , at the World Economic Forum   "The ... driven by big data and powered by artificial intelligence and this trend is ... discussed the ,Hospital of the Future, at the concluding day of the 47 ...
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic ... Forecasts, 2013 - 2024" report to their offering. ... The global clinical laboratory ... Introduction of innovative solutions on the grounds of maximum ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... general gynecological care and gynecological services for women of all ages. ... for a wide variety of reproductive services from routine health screenings to diagnosing ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: ... “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. Robert ... Church for thirteen years, a preacher for over nineteen, a pastor for over fifteen ...
(Date:1/22/2017)... ... , ... Medical lab testing through hospitals and other traditional methods ... will take days to arrive to the end customer, having to travel through medical ... lab tests, bypassing the cost and delay of traditional means. Now all employees of ...
(Date:1/21/2017)... ... 21, 2017 , ... Phytocéane invites you to take an exotic ... the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian ... and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the ...
Breaking Medicine News(10 mins):